Document is current
Any future updates will be listed below
-
Authors
Cooper, Ryan https://orcid.org/0000-0002-5473-2392
Ramaswami, Dhruv https://orcid.org/0000-0002-9798-2877
Thomas, Jacob S. https://orcid.org/0000-0002-8420-366X
Nieva, Jorge J. https://orcid.org/0000-0003-1605-4719
Hsu, Robert https://orcid.org/0000-0003-3957-6106
-
Funding
Funding for this research was provided by:
USC Norris Comprehensive Cancer Center (Core) Grant (P30 CA014089)
- License Information
-
More Information
Article History
Received: 17 August 2024
Accepted: 19 November 2024
First Online: 21 November 2024
Declarations
:
: This study was conducted in accordance with the ethical standards as defined by the 1964 Declaration of Helsinki and its later amendments. Ethics approval for use of our lung cancer database was granted by the University of Southern California’s Institutional Review Board (IRB): HS-15-00200 Retrospective Analysis of Lung Cancer Patients Treated at LAC-USC Medical Center and USC Norris Comprehensive Cancer Center. IRB approval was initially submitted on 3/26/2015 and has been approved annually with the last approval date of 6/13/2024 and expiration date of 6/12/2025. The need for informed consent was waived as the study was retrospective in nature.
: Dr. Robert Hsu is a consultant for Targeted Oncology and Takeda and received honoraria from DAVA Oncology and The Dedham Group. Dr. Jorge Nieva is a consultant for Aadi Biosciences, Affyimmune, ANP Technologies, Astra Zeneca, BioAtla, G1 Therapeutics, Genetech, Kalivir Mindmed, Naveris, Sonofi, receives research support from Genetech and Merck, owns intellectual property with Cansera, and has ownership interests with Cansera, Indee Bio, Quantgene, Amgen, Johnson & Johnson, and Novartis. Jacob Thomas is a consultant for Coherus BioSciences, Inc. and Kura Oncology, Inc. The remaining authors have no conflicts of interest to disclose.
